Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Myeloid Leukemia: early-phase trial registry
159 of 307 indexed Acute Myeloid Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #26 of 28,707 conditions by registered trial count.
307 US clinical trials · 159 currently recruiting · #26 of 28,707 conditions by registered trial count
Acute Myeloid Leukemia: 307 US clinical trials tracked, 159 recruiting.
Acute Myeloid Leukemia is the subject of 307 registered US clinical trials on ClinicalTrials.gov, 159 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 265 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 38 of these trials.
Enrollment posture brief
Registry condition acute-myeloid-leukemia
OPEN 159 | RECR 52% | LATE 13 | EARLY 265 | RANK #26 | SPON 38
Volume-matched condition peers
Nearest open-share peer: Aortic Stenosis (52% recruiting · 27 trials)
Acute Myeloid Leukemia lists 159 open slots (52% of 307 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute Myeloid Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute Myeloid Leukemia is recruiting above its size-band peers.
159 of 307 indexed trials (51.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Acute Myeloid Leukemia trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 38 of 307 trials (12.4%). 128 distinct sponsors appear on at least one study for this condition label.
-
Most Acute Myeloid Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 49 among the 307 trials that report a genuine target (sentinel values excluded). 223 of those (72.6%) plan for fewer than 100 participants.
-
Acute Myeloid Leukemia research is mostly interventional.
290 interventional and 17 observational studies make up this index (94.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
307 total, page 3 of 7
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
University of Washington
NCT03737955
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
Joanna Yi
NCT07059975
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Vincerx Pharma
NCT06034275
Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
City of Hope Medical Center
NCT03728335
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
City of Hope Medical Center
NCT06815003
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
Norman J. Lacayo
NCT05101551
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
Montefiore Medical Center
NCT07283094
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
NCT06195891
Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT06445907
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
OHSU Knight Cancer Institute
NCT04659616
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
Masonic Cancer Center, University of Minnesota
NCT07008638
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
M.D. Anderson Cancer Center
NCT05834244
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
City of Hope Medical Center
NCT05263284
Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant
Huda Salman
NCT06197672
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Fred Hutchinson Cancer Center
NCT06034470
Home Blood Transfusions
Thomas Jefferson University
NCT07121140
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
St. Jude Children's Research Hospital
NCT06810583
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
University of California, Davis
NCT07304011
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
Celyad Oncology
NCT04167696
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Taiho Oncology
NCT04953910
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
City of Hope Medical Center
NCT06575296
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
NCT05672147
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
NCT04282187
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Eric Stephen Winer, MD
NCT05703542
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
M.D. Anderson Cancer Center
NCT06616636
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
Omar Aljitawi
NCT03964506
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
OHSU Knight Cancer Institute
NCT06357182
Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
Remedy Plan
NCT07107126
Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Stanford University
NCT06551584
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
University of Virginia
NCT07270978
Revumenib in Combination With 7+3 + Midostaurin in AML
Richard Stone, MD
NCT06313437
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
University of Wisconsin, Madison
NCT02508038
Ziftomenib Maintenance Post Allo-HCT
Massachusetts General Hospital
NCT06440135
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT06448013
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
Brian Jonas
NCT04905810
Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)
Suhu Liu
NCT06297551
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
Benjamin Tomlinson
NCT06129734
Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)
Children's Hospital Medical Center, Cincinnati
NCT05580601
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
University of Alabama at Birmingham
NCT07044544
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Fred Hutchinson Cancer Center
NCT07046078
Cladribine Venetoclax in Monocytic AML
University of Colorado, Denver
NCT06232655
Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML
Nationwide Children's Hospital
NCT05503134
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
University of Florida
NCT05800210
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
H. Lee Moffitt Cancer Center and Research Institute
NCT05558124
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
Seattle Children's Hospital
NCT05105152
Phase I Study of HC-7366 for Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT06285890
CER-1236 in Patients With Acute Myeloid Leukemia (AML)
CERo Therapeutics Holdings
NCT06834282
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Terrence J Bradley, MD
NCT05597306
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Taiho Oncology
NCT04953897
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
Justin Watts, MD
NCT06782542
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 160 |
| Phase 2 | 105 |
| Phase 3 | 12 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute Myeloid Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute Myeloid Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute Myeloid Leukemia page
307 registered trials, 159 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 159 Acute Myeloid Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Acute Myeloid Leukemia trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Myeloid Leukemia condition card totals 307 registered trials; most-linked intervention Venetoclax; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.